GATA3 expression in estrogen receptor ⍺-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival - 21/08/11
, Ingunn M. Stefansson, MD, PhD b, Lars A. Akslen, MD, PhD b, c, Helga B. Salvesen, MD, PhD a, d
Reprints: Ingeborg Bøe Engelsen, MD, Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, NorwayRésumé |
Objective |
The transcription factor GATA3 has recently been found to be involved in the carcinogenesis for numerous cancers. We investigated this marker in relation to clinicopathologic characteristics, hormone receptors, other biomarkers, and survival in endometrial carcinoma.
Study Design |
A population-based study of 316 endometrial carcinomas with complete follow-up was studied for GATA3, estrogen receptor (ER)-⍺, ERβ2, and progesterone receptor (PR) expression.
Results |
Positive GATA3 expression in hysterectomy specimens significantly correlated to high International Federation of Gynecology and Obstetrics stage, serous papillary/clear cell subtypes, high histologic grade, loss of PR expression, aneuploidy, high proliferation, pathologic p53 and p16 expression, and poor prognosis (P = .003). Loss of hormone receptors significantly correlated with aggressive phenotype and poor prognosis. Pathologic expression of GATA3/ER⍺ in combination added independent prognostic information.
Conclusion |
GATA3 expression is associated with an aggressive phenotype and adds independent prognostic information in addition to receptor status. Further studies of its value in tailored treatment protocols seem justified.
Le texte complet de cet article est disponible en PDF.Key words : endometrial carcinoma, estrogen receptor-β2(cx), GATA3, prognostic markers, steroid receptors, survival
Plan
| The study was supported by Helse Vest grants 911069 and 911351 and the Norwegian Cancer Society. |
|
| Cite this article as: Engelsen IB, Stefansson IM, Akslen LA, et al. GATA3 expression in estrogen receptor ⍺-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 2008;199:543.e1-543.e7. |
Vol 199 - N° 5
P. null - novembre 2008 Retour au numéro
Article précédent
- A clinical pathway for postoperative management and early patient discharge: does it work in gynecologic oncology?
- Dana M. Chase, Sarah Lopez, Christina Nguyen, Gordon A. Pugmire, Bradley J. Monk
- Reoperation for urinary incontinence
- Michael Fialkow, Rebecca Gaston Symons, David Flum
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?